News Release
min read

BSF Enterprise Announces Interim Results

Published on
Jun 29, 2023
This article is sponsored by:

BSF (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is pleased to announce its unaudited interim results for the six months ending 31 March 2023.


·    Produced three small prototype fillets of meat in November 2022

·    Produced the UK's first full-sized fillet of cultivated meat in February 2023

·    Doubled lab space to 2,400 square feet, increasing production capacity to 2,500 litres of City-Mix per annum, equivalent to 60,000 litres of end-product

·    Engaged with over 70 Cellular Agriculture companies with 26 progressing to business opportunities

·    Partnership with QKine, combining technologies to expedite the creation of affordable cultivated meat

·    Partnership with New Harvest to accelerate routes to market

·    Signed distribution partners covering Germany, Austria, Switzerland, Australia, New Zealand and Fiji

Post Period End Highlights

·    Produced two full-sized fillets and a strip of pork which were tested at a technical event

·    Produced cultivated skin to the thickness of leather

·    Raised £2.9 million in oversubscribed placing

·    Signed first PoC contract with company in the leather industry and have engaged with many more

·    Cash balance of £2.7 million as at the date of this announcement

·    Produced two full fillets and a strip of pork which were tested at a technical event

·    Admitted to trading on the OTCQB exchange in the US under the symbol BSFAF

Che Connon, Managing Director of BSF Enterprise and CEO at 3D Bio Tissues, commented:

"The period under review has been one of significant progress on both technical and commercial fronts. Technical milestones have included us producing the UK's first 100% cultivated steak, an enormous step forward for our industry, as well as skin products thick enough to be used to make leather goods. Commercial progress has been demonstrated through numerous partnerships and proof-of-concepts as well as the signing of our first contracts, while expanding our sales channels both direct and indirect.

"Activity has continued apace since the end of the period and we have no intention of slowing, given the many opportunities available to us and the huge global potential for our innovative technology.  We have a strong balance sheet which will support our well-defined growth strategy and we look forward to updating the market on future successes."

For further enquiries, please

Stay connected and informed.

Get the latest company news, scientific developments, product launches, and more direct to your inbox with our free weekly newsletter.

Thank you! You will hear from us soon!
Oops! Something went wrong while submitting the form.
Cell Based News
Showcasing the scientific breakthroughs, exciting companies and industry pioneers leading the cell based food and materials revolution.